Treatment of Vulvar Lichen Sclerosus With Topical Ruxolitinib: A Single‐Center Study
The Journal of Dermatology · 2026-11 · 53 (11) · 1691-1695
DOI: 10.1111/1346-8138.70460 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Dermatology, online erschienen am 12.08.2026. Verfasst von Alessia Paganelli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Regenerative and Immunological Dermatology (CEDRI), IDI-IRCCS Istituto Dermopatico Dell'immacolata, Rome, Italy. Hauptthemen laut MEDLINE: Pyrazoles, Vulvar Lichen Sclerosus, Janus Kinase Inhibitors. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Lichen sclerosus (LS) is a chronic inflammatory dermatosis of the anogenital region with limited therapeutic options. Emerging evidence implicates dysregulation of the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway in LS pathogenesis, supporting investigation of targeted therapies. We report a series of 6 patients treated with topical ruxolitinib for vulvar LS, applied twice daily. Clinical outcomes were assessed using the Clinical Scoring System (CSS) and Patient Global Assessment (PtGA) over a mean follow‐up of 7.5 months. All patients reported early symptomatic improvement in pruritus and burning. In parallel, PtGA scores showed significant improvement ( p < 0.05). No local or systemic adverse events were observed. These findings suggest that topical JAK–STAT inhibition may represent a steroid‐sparing option for achieving symptomatic improvement in LS, particularly in patients with concomitant autoimmune conditions. Larger controlled studies are warranted to confirm these preliminary observations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Regenerative and Immunological Dermatology (CEDRI), IDI-IRCCS Istituto Dermopatico Dell'immacolata, Rome, Italy.
- Department of Life Sciences, Health and Health Professions, Link Campus University, Rome, Italy.
- Rare Diseases Unit, IDI-IRCCS Istituto Dermopatico Dell'immacolata, Rome, Italy.
- Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy.
- Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy.
- Clinical Trial Center, IDI-IRCCS Istituto Dermopatico Dell'immacolata, Rome, Italy.
ORCID-Profile: Alessia Paganelli, Cristina Cristofoletti, Mauro Picardo
Zitieren
APA
Paganelli, A., Colonna, L., Didona, B., Pellacani, G., Longo, C., Cristofoletti, C., & Picardo, M. (2026). Treatment of Vulvar Lichen Sclerosus With Topical Ruxolitinib: A Single‐Center Study. The Journal of Dermatology, 53(11), 1691-1695. https://doi.org/10.1111/1346-8138.70460
Vancouver
Paganelli A, Colonna L, Didona B, Pellacani G, Longo C, Cristofoletti C, et al. Treatment of Vulvar Lichen Sclerosus With Topical Ruxolitinib: A Single‐Center Study. The Journal of Dermatology. 2026;53(11):1691-1695. doi:10.1111/1346-8138.70460
BibTeX
@article{Paganelli2026,
author = {Paganelli, Alessia and Colonna, Laura and Didona, Biagio and Pellacani, Giovanni and Longo, Caterina and Cristofoletti, Cristina and Picardo, Mauro},
title = {Treatment of Vulvar Lichen Sclerosus With Topical Ruxolitinib: A Single‐Center Study},
journal = {The Journal of Dermatology},
year = {2026},
volume = {53},
number = {11},
pages = {1691--1695},
doi = {10.1111/1346-8138.70460}
}
EUVIMED